Hints and tips:
...“Nobody at Pfizer ever told Mr Dagar, who was on the ‘blinded’ side, the results of the Paxlovid trial,” he added....
...The UK Medicines and Healthcare products Regulatory Agency could approve the Pfizer/BioNTech vaccine as early as this week, while US regulators are due to rule this month on both the Moderna and Pfizer/BioNTech...
...Additional reporting by Joe Miller in Frankfurt...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Jon Miller, an analyst at Evercore, said the vaccines’ differences had not been “convincingly demonstrated” and the “horse race” between Moderna, Pfizer and AstraZeneca was not driving their stock....
...Israel signed a deal with Pfizer to get more doses in exchange for studying its population, as it gets vaccinated....
...BioNTech and Pfizer have said there is no evidence that spreading out the doses works....
...BioNTech and Pfizer have already sold more than 1bn of the doses to be produced this year....
...The Covid-19 vaccine developed by BioNTech and Pfizer is likely to be effective against a rapidly spreading strain of the virus that was first discovered in the UK, a laboratory-based study by the companies...
...The US and UK signed deals with BioNTech/Pfizer months earlier in July....
...As European regulators prepared to approve the vaccine, developed with Pfizer, Brussels attempted to secure more doses but BioNTech’s capacity to deliver hinged on the readiness of the Marburg plant to start...
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Albert Bourla, Pfizer’s chief executive, said the companies were ready to start delivering doses to sites across the EU....
...Pfizer is part of the programme but chose not to take funding, just a pre-order that will be paid for when the vaccines are delivered....
...Last month it warned against the activation of the emergency use authorisation just deployed by the UK, amid concerns that Hungary would exploit it to fast-track Russia’s Sputnik V vaccine without full safety...
...Unlike some of its rivals, BioNTech and Pfizer have not promised to supply the vaccine on a not-for-profit basis....
...Shares in BioNTech rose 5.6 per cent to $100.52, while Pfizer closed up 1.4 per cent to $36.70 in New York....
...Pfizer confirmed the temporary change in guidance while a probe was under way....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Pfizer and BioNTech have said that they can manufacture 50m doses of their two-shot vaccine this year, and a further 1.3bn in 2021....
...Distribution of the BioNTech/Pfizer vaccine would be “logistically complicated”, cautioned Sir Simon at NHS England, as it has to be transported at -70C....
...Pfizer and BioNTech’s vaccine, which relies on novel mRNA technology, is administered in two separate shots....
...Shares in Pfizer rose 7.6 per cent, while BioNTech’s increased 7.9 per cent. Pfizer and BioNTech were already co-operating on a flu vaccine when the Covid-19 pandemic emerged....
...BioNTech’s comments echoed those of its partner Pfizer, which also called the UK decision into question last week by restating the recommended 21-day period between doses....
...Additional reporting by Guy Chazan in Berlin, Joe Miller in Frankfurt and Daniel Dombey in Madrid...
International Edition